Expertise in
26
conditions

Dr. David Quinn

Oncology
Office
1441 Eastlake Ave Ste 3440, 
Los Angeles, CA 
Clinical Trials:Currently Recruiting for 4 Trials
Offers Telehealth
Expertise in
26
conditions
Office
1441 Eastlake Ave Ste 3440, 
Los Angeles, CA 

Overview

David Quinn is an Oncologist in Los Angeles, California. Dr. Quinn is highly rated in 26 conditions, according to our data. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostatectomy, and Nephrectomy.

His clinical research consists of co-authoring 211 peer reviewed articles and participating in 30 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Office
1441 Eastlake Ave Ste 3440, Los Angeles, CA 90089
Other Locations
USC Care Medical Group Inc
1520 San Pablo St, Los Angeles, CA 90033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drug: Olaparib
Study Phase: Phase 2
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Avelumab, Peposertib, Radium-223
Study Phase: Phase 1/Phase 2
Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Enrollment Status: Recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Procedure
Study Phase: Phase 3
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Eribulin Mesylate
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy
A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Dietary supplement, Other, Procedure
Study Phase: Not Applicable
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer
Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Drug, Radiation
Study Drug: Enzalutamide
Study Phase: Phase 2
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma
Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Radiation, Other, Biological
Study Drugs: Aldesleukin, Entinostat
Study Phase: Phase 1/Phase 2
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Other, Drug
Study Drug: Eribulin Mesylate
Study Phase: Phase 1/Phase 2
Short-Term Fasting Prior To Platinum-based Chemotherapy: Feasibility and Impact on Toxicity
Short-Term Fasting Prior To Platinum-based Chemotherapy: Feasibility and Impact on Toxicity
Enrollment Status: Terminated
Publish Date: June 02, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drugs: 177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Study Phase: Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, Vorinostat
Study Phase: Phase 1
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Randomized, Open Label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 Plus Entinostat in Advanced Renal Cell Carcinoma
A Phase II Randomized, Open Label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 Plus Entinostat in Advanced Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2023
Intervention Type: Drug
Study Drugs: Entinostat, Interleukin-2
Study Phase: Phase 2
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers
Enrollment Status: Terminated
Publish Date: August 25, 2023
Intervention Type: Device, Drug
Study Phase: Phase 1
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Enrollment Status: Completed
Publish Date: August 21, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Docetaxel
Study Phase: Phase 3
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Unknown
Publish Date: April 27, 2022
Intervention Type: Biological
Study Drug: Recombinant EphB4-HSA Fusion Protein
Study Phase: Phase 2
A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers
A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers
Enrollment Status: Terminated
Publish Date: November 24, 2021
Intervention Type: Procedure, Other, Biological
Study Drug: Recombinant EphB4-HAS Fusion Protein
Study Phase: Phase 1
A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)
A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)
Enrollment Status: Terminated
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Enrollment Status: Terminated
Publish Date: December 10, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 23 Less Clinical Trials

211 Total Publications

Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.
Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.
Journal: Cancer chemotherapy and pharmacology
Published: May 23, 2025
Similar Doctors
Expertise in
31
conditions
Dr. Mark Agulnik
Oncology
Expertise in
31
conditions
Dr. Mark Agulnik
Oncology

USC Norris Comprehensive Cancer Center And Hospital

1441 Eastlake Ave, 
Los Angeles, CA 
 (0.2 miles away)
323-865-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Agulnik is an Oncologist in Los Angeles, California. Dr. Agulnik is highly rated in 31 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Angiosarcoma, Osteotomy, and Colonoscopy.

Expertise in
10
conditions
Dr. Thomas Coates
Hematology | Oncology
Expertise in
10
conditions
Dr. Thomas Coates
Hematology | Oncology

Office

4650 W Sunset Blvd # 54, 
Los Angeles, CA 
 (5.6 miles away)
323-361-4624
Languages Spoken:
English
See accepted insurances

Thomas Coates is a Hematologist and an Oncologist in Los Angeles, California. Dr. Coates is highly rated in 10 conditions, according to our data. His top areas of expertise are Hemoglobinopathy, Anemia, Congenital Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Gary Schiller
Expertise in
65
conditions
Dr. Gary Schiller
Oncology
Expertise in
65
conditions
Dr. Gary Schiller
Oncology

UCLA Health Bowyer Oncology Center

200 UCLA Medical Plz Ste 120, 
Los Angeles, CA 
 (13.8 miles away)
310-206-6745
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gary Schiller is an Oncologist in Los Angeles, California. Dr. Schiller is highly rated in 65 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. David Quinn

How do I make an appointment with Dr. David Quinn?

You can book an appointment with Dr. David Quinn by calling their office at 323-865-3956. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David Quinn a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David Quinn is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David Quinn specialize in?

While Dr. David Quinn is a Oncology, they have specific expertise in Prostate Cancer, Renal Cell Carcinoma (RCC), and Urothelial Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. David Quinn participate in research or clinical trials?

Yes. Dr. David Quinn has published 211 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. David Quinn's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David Quinn accept my insurance?

Dr. David Quinn accepts most major insurance plans, including Aetna and Humana. We recommend calling the office directly at 323-865-3956 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Quinn's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 15 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile